Eli Lilly and Company (NYSE:LLY) Stock Position Increased by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 24.7% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 1,869 shares of the company’s stock after buying an additional 370 shares during the period. Loomis Sayles & Co. L P’s holdings in Eli Lilly and Company were worth $1,656,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of LLY. Virtu Financial LLC acquired a new position in Eli Lilly and Company during the 1st quarter valued at about $2,138,000. LRI Investments LLC acquired a new position in Eli Lilly and Company during the 1st quarter valued at about $81,000. ARQ Wealth Advisors LLC acquired a new position in Eli Lilly and Company during the 1st quarter valued at about $226,000. FSA Advisors Inc. acquired a new position in Eli Lilly and Company during the 1st quarter valued at about $506,000. Finally, Northwest Bank & Trust Co acquired a new position in shares of Eli Lilly and Company in the 1st quarter worth approximately $78,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the topic of several recent research reports. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Barclays lowered their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Guggenheim lifted their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Finally, Citigroup raised their target price on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a report on Friday, October 25th. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,007.94.

Eli Lilly and Company Price Performance

NYSE LLY opened at $788.35 on Thursday. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The stock has a market capitalization of $748.40 billion, a PE ratio of 85.23, a price-to-earnings-growth ratio of 2.86 and a beta of 0.43. The company has a 50 day moving average price of $856.96 and a two-hundred day moving average price of $869.83. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. Eli Lilly and Company’s revenue was up 20.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.10 earnings per share. As a group, equities analysts predict that Eli Lilly and Company will post 13.2 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.66%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio is 56.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.